Claritev Corporation (CTEV) Q3 2026 earnings review
Claritev raises its sales outlook, but its debt keeps rising
Claritev, a healthcare technology firm that audits medical claims for insurers, accelerated its sales growth while its debt balance kept climbing. Third-quarter revenue rose 9% to $268 million, or 11% by our math after stripping a one-time gain from last year's base. Finance chief Doug Garis raised the full-year sales outlook by $31 million at the middle of the range and introduced a $1.1 billion revenue target for 2027, a year ahead of plan.
| Sales from businesses owned a year ago (ex one-off) | +11.4% +9.1% reported ($268.3M) |
|---|---|
| Adjusted EBITDA margin | 60.4% 63.1% a year ago |
| Total carrying debt | $4.71B up $117M since December |
| Full-year 2026 revenue outlook | Raised $30.5M preliminary 2027 view: $1.1B |
⚖️ Verdict: 🟢 Bullish
The story got better because top-line momentum cleared a tough comparison and management backed up its first-half contract bookings with a 2027 revenue target. That shows new contracts are converting into revenue faster than the company's March plan assumed. The bad news: service and overhead costs cut the Adjusted EBITDA margin by nearly 3 percentage points, antitrust legal bills more than doubled, and credit-line draws pushed total debt up another $39 million while unrestricted cash fell to $10 million.
The question now is whether revenue growth can turn into enough cash to stop the debt from growing. Bulls argue that rising earnings from new contracts will lower the debt ratio over time, while bears note that nine-month free cash flow is negative $64 million and hitting the full-year cash plan requires a $79 million fourth quarter by our math. The upcoming quarterly filing's client-concentration note and fourth-quarter cash collections will settle it.
🐂 Bull Case
Underlying Sales Accelerated Through a Tough Comparison
"People sometimes describe Claritev as a transformation or a turnaround story. I describe it differently: Claritev is a growth company," chief executive Travis Dalton said. The healthcare claims processor backs up his claim on the top line. Third-quarter sales rose 9.1% from a year ago to $268.3 million, and climbed 4.2% from the second quarter even though management had suggested modeling sequential sales flat.
The comparison period included a one-time gain of about $5 million in its property and casualty network business during the third quarter of 2025. Stripping that one-off from last year's base, sales from businesses it owned a year ago grew 11.4% by our math, accelerating from 9.0% underlying growth in the second quarter.
What to watch: the revenue breakdown by service line and client concentration in the quarterly filing. Those tables will show whether "growth across our solutions and our verticals" drove the acceleration or if the largest health-plan client accounted for most of the gain again.
Third Straight Raise Puts 2027 Target Early
Finance chief Doug Garis raised the full-year 2026 revenue forecast by $30.5 million at the middle of the range, to between $1.038 billion and $1.043 billion. That follows two smaller raises earlier this year and lifts expected full-year growth to 7.8% by our math. Garis also said the claims analytics group is "running approximately a year ahead of our March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion."
- First-quarter 2026 outlook raise: +$2.5 million at the middle of the range
- Second-quarter 2026 outlook raise: +$17.5 million at the middle of the range
- Third-quarter 2026 outlook raise: +$30.5 million at the middle of the range
- Implied fourth-quarter 2026 revenue: $270.0 million at the middle of the range, up 9.5% from a year ago by our math
The expanding raises matter because previous plans implied a second-half slowdown. Instead, the new outlook points to 12.0% underlying growth in the fourth quarter by our math once last year's $5.4 million one-time gain is removed. The $1.1 billion preliminary target for 2027 implies 5.7% growth over the new 2026 midpoint, showing that record first-half contract bookings are converting into billed revenue.
What to watch: full-year annualized contract value bookings on the fourth-quarter call. Reaching or beating the $100 million bookings target will show whether the sales pipeline supports another series of raises in 2027.
🐻 Bear Case
Higher Service Costs Squeezed Operating Margins
Dalton highlighted "dozens of AI agents already at work inside our workflows" and showcased "Transparency-Based Pricing, our Healthcare Intelligence platform, and expanded Medicare Advantage offerings" at its client conference. Earlier this year, management said artificial intelligence tools were multiplying engineering output and would drive operating leverage across the claims platform.
The cost lines moved the other way this quarter. Adjusted EBITDA — earnings before interest, taxes, depreciation, amortization and one-offs — grew 4.4% to $162.0 million, Less than half the 9.1% revenue pace. The Adjusted EBITDA margin dropped 2.7 percentage points from a year ago to 60.4%. Cost of services rose 0.8 percentage points of revenue to 26.0%, and general and administrative overhead climbed 0.3 percentage points to 24.7%, by our math.
Lapping last year's high-margin one-time revenue explains part of the drop, but new bookings in lower-margin services and ongoing hiring are absorbing the top-line gains. What to watch: Adjusted EBITDA margin in the fourth quarter, which the full-year outlook puts at 60.3% by our math. A reading stuck near 60% would confirm that newer product lines carry structurally lower margins.
Debt Rose While Cash Dropped to $10M
Garis reiterated a commitment to "maintaining our focus on profitability and improving free cash flow conversion." Claritev carries a heavy debt load from past buyouts and pays semi-annual cash interest in the first and third quarters, making those periods cash drains and leaving little room for error.
- Total carrying debt: $4,711.9 million, up $39.1 million from last quarter and $116.8 million since December by our math
- Revolving credit facility balance: $95.0 million, up from $70.0 million in June and $20.0 million in December
- Unrestricted cash on hand: $10.1 million, down from $39.2 million a year ago
- Third-quarter free cash flow: -$25.8 million, a wider outflow than -$16.3 million a year ago
Debt keeps climbing because parts of the loan structure add unpaid interest directly to the principal balance ($16.2 million of non-cash interest this quarter), and the healthcare technology group borrowed a net $25.0 million on its credit line to fund $130.2 million of cash interest and $44.4 million of capital spending. Even before interest payments, unlevered free cash flow fell 7.8% from a year ago to $104.4 million.
What to watch: fourth-quarter free cash flow, which must reach $78.7 million by our math to hit the middle of the raised $10 million to $20 million full-year plan. Last year's fourth quarter generated $36.4 million, so falling short would keep credit-line borrowings elevated.
Antitrust Legal Bills More Than Doubled
Claritev defends against consolidated federal antitrust lawsuits alleging it conspired with health insurers to hold down out-of-network payments to medical providers. The company adds those legal bills and its Vision 2030 restructuring spend back to Adjusted EBITDA each quarter, treating both as outside normal operations.
Legal expenses for antitrust matters jumped to $10.3 million in the third quarter, up 153.3% from $4.1 million a year ago by our math and up from $2.6 million in the second quarter. For the first nine months of 2026, antitrust legal costs reached $21.5 million against $8.5 million in the prior-year period. Vision 2030 transformation costs added another $8.0 million of adjustments this quarter, though that figure fell from $13.9 million a year ago.
What to watch: antitrust legal spend and litigation footnote updates in the upcoming quarterly filing. Rising quarterly legal bills Drain actual cash regardless of non-GAAP exclusions.
Risks this quarter didn't answer
Four standing items from our prior work cannot be read from the earnings release alone because Claritev reports segment tables, customer concentration and bookings in its quarterly filing and conference call remarks.
- Single-client concentration: one customer accounted for 35.0% of second-quarter revenue; the quarterly filing's concentration note will show whether the third-quarter beat relied even more heavily on that client.
- Revenue by pricing model and service line: percentage-of-savings (PSAV) revenue growth and the split across Network, Claims Intelligence, and Payment and Revenue Integrity await the filing's revenue disaggregation table.
- Third-quarter contract bookings: management reported over $70 million of annualized contract value bookings in the first half against a $100 million full-year target; third-quarter bookings were not printed in the release.
- Interest-rate swap expiration: $800 million of swaps fixing floating-rate debt matured in August 2026; the filing's debt footnote will show the new cash interest rate.
💲 Other KPIs
Unbilled Independent Dispute Resolution fees — money earned from federal surprise-medical-bill arbitration that has not yet been invoiced — rose to $20.9 million on the balance sheet. That is up from $18.0 million in June and up 98.1% from $10.6 million at the end of 2025 by our math, showing strong arbitration volume but tying up working capital.
Operating profit more than doubled from $10.1 million a year ago, lifting the operating margin by 3.6 percentage points to 7.7% by our math. Because intangible amortization stayed flat at $85.9 million and transformation costs fell, revenue growth flowed through to GAAP operating profit, narrowing the net loss by 11.4% to $61.8 million.
Weighted average basic and diluted shares rose 3.0% from a year ago to 17.0 million by our math, up slightly from 16.96 million in the second quarter. Stock-based compensation of $21.5 million over the first nine months outweighed $3.5 million of share buybacks earlier in the year.
🔮 Guidance
Raised. The middle of the range moved up $30.5 million to $1.0405 billion, or 7.8% full-year growth by our math. By our math, that leaves $270.0 million for the fourth quarter, up 9.5% reported and 12.0% excluding last year's one-time gain. It is the third raise this year, and each move has grown larger: +$2.5M, +$17.5M, +$30.5M.
New. Garis introduced an early 2027 revenue target of $1.1 billion, saying the claims processor is running a year ahead of its March 2026 Investor Day plan. By our math, $1.1 billion represents 5.7% growth over the middle of the raised 2026 outlook.
Raised. The middle of the range rose $12.5 million to $627.5 million, or 4.1% growth for the year by our math. By our math, that leaves $162.8 million for the fourth quarter, up 7.6% from a year ago at a 60.3% margin, confirming that about half of the extra revenue raise is absorbed by higher operating expenses.
Raised. Management lifted the range by $5 million to a midpoint of $15 million. Because free cash flow over the first nine months was -$63.7 million, hitting the middle of the plan requires $78.7 million of free cash flow in the fourth quarter by our math, more than double the $36.4 million generated in the fourth quarter of 2025.
Raised at the bottom end. The lower bound moved up $5 million, raising the middle of the range by $2.5 million to $167.5 million as the company continues investing in its platform and AI tools.
Unchanged. The expected full-year tax benefit rate stays at 24% to 28%, compared with a 22.8% effective tax benefit recorded in the third quarter.
❓ Key Questions
Did one customer drive the third-quarter revenue beat again?
One client made up 35.0% of revenue in the second quarter and drove most of the surprise-billing volume gain. Investors need the third-quarter concentration figure from the quarterly filing to see if growth is broadening as management claims.
How will fourth-quarter free cash flow reach $79 million?
Nine-month free cash flow sits at -$63.7 million, so hitting the $15 million full-year midpoint requires $78.7 million in the fourth quarter by our math — more than twice last year's fourth-quarter cash generation.
What were third-quarter contract bookings and segment growth rates?
The earnings release omitted quarterly annualized contract value bookings and the revenue split across Network, Claims Intelligence, and Payment and Revenue Integrity. Both are needed to check progress toward the $100 million full-year bookings target.
Why did antitrust legal expenses jump to $10.3 million?
Legal bills for the consolidated antitrust lawsuit more than doubled from a year ago and quadrupled from the second quarter. Management needs to clarify whether discovery milestones or settlement talks drove the increase.